Stocktoria
Kiniksa Pharmaceuticals International, plc KNSA
Kiniksa Pharmaceuticals International, plc (KNSA) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $677.6M at a 8.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.16 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-29 | Wedbush | Outperform (main) |
| 2026-04-29 | Canaccord Genuity | Buy (main) |
| 2026-04-29 | Citigroup | Buy (main) |
| 2026-04-29 | Wedbush | Outperform (main) |
| 2026-04-29 | Wells Fargo | Overweight (main) |
| 2026-04-28 | Jefferies | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.508 |
| Retained earnings / assets | -0.605 |
| EBIT / assets | 0.101 |
| Equity / liabilities | 2.896 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc | 6/9 | 5.08 | 77.2 | +60.1% |
| RARE | Ultragenyx Pharmaceutical Inc. | 4/9 | -9.61 | — | +20.2% |
| AXSM | Axsome Therapeutics, Inc. | 4/9 | -5.64 | — | +65.5% |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | 3/9 | 5.11 | — | +8.6% |
| AMPH | Amphastar Pharmaceuticals, Inc. | 6/9 | 4.82 | 9.8 | -1.7% |
| PCRX | Pacira BioSciences, Inc. | 8/9 | 3.08 | 141.1 | +3.6% |
| TGTX | TG THERAPEUTICS, INC. | 4/9 | 2.04 | 19.1 | +87.3% |
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
FAQ
Is KNSA financially healthy?
Kiniksa Pharmaceuticals International, plc's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does KNSA pay a dividend?
No, Kiniksa Pharmaceuticals International, plc does not currently pay a dividend.
How profitable is KNSA?
In FY2025, Kiniksa Pharmaceuticals International, plc had a net margin of 8.7% and a return on equity of 10.4%.
What is KNSA's P/E ratio?
Kiniksa Pharmaceuticals International, plc's trailing price-to-earnings (P/E) ratio is about 77.2×, based on its latest annual earnings.
What is the analyst price target for KNSA?
The average Wall-Street price target for Kiniksa Pharmaceuticals International, plc is $65.12, about 16.7% below the recent price, from 8 analysts (consensus: strong buy).
Is KNSA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Kiniksa Pharmaceuticals International, plc: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 77.2×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.